John Mumm

President & CEO at Deka Biosciences

John has spent 24 years researching and developing various technologies associated with IL-10. His work experience included various leadership roles at Anergen, Introgen Therapeutics, Bacterial BarCodes, Schering-Plough, Merck, Targenics, ARMO BioSciences, ACIR BioSciences, and MedImmune/AstraZeneca. John’s primary focus has been on discovery research at the interface between cancer biology and the adaptive immune response.

Links


Org chart


Teams


Offices

This person is not in any offices


Deka Biosciences

Deka Biosciences, Inc., is an early-stage biotechnology company focused on generating the next generation targeted cytokine therapies to treat cancer and inflammatory diseases.


Industries

Employees

11-50

Links